INGN 201: Phase I and Phase II data

In a U.S. Phase II trial of intratumoral injections of INGN 201 plus radiation in 17 lung cancer patients, 9 patients showed >50 percent regression of their primary tumor 3 months after completion of treatment, while 5 of those patients showed >50 percent regression of their total disease. A total of 12 of 15 patients who completed treatment showed no active cancer in their primary tumors. Introgen said that the historical tumor control rate with radiation alone is <20 percent. Data were presented at the American Society of Clinical Oncology meeting in New Orleans. ...